Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309462985> ?p ?o ?g. }
- W4309462985 endingPage "5651" @default.
- W4309462985 startingPage "5651" @default.
- W4309462985 abstract "In the present study, SibuDAB, an albumin-binding PSMA ligand, was investigated in combination with actinium-225 and the data were compared with those of [225Ac]Ac-PSMA-617. In vitro, [225Ac]Ac-SibuDAB and [225Ac]Ac-PSMA-617 showed similar tumor cell uptake and PSMA-binding affinities as their 177Lu-labeled counterparts. The in vitro binding to serum albumin in mouse and human blood plasma, respectively, was 2.8-fold and 1.4-fold increased for [225Ac]Ac-SibuDAB as compared to [177Lu]Lu-SibuDAB. In vivo, this characteristic was reflected by the longer retention of [225Ac]Ac-SibuDAB in the blood than previously seen for [177Lu]Lu-SibuDAB. Similar to [225Ac]Ac-PSMA-617, [225Ac]Ac-SibuDAB was well tolerated at 30 kBq per mouse. Differences in blood cell counts were observed between treated mice and untreated controls, but no major variations were observed between values obtained for [225Ac]Ac-SibuDAB and [225Ac]Ac-PSMA-617. [225Ac]Ac-SibuDAB was considerably more effective to treat PSMA-positive tumor xenografts than [225Ac]Ac-PSMA-617. Only 5 kBq per mouse were sufficient to eradicate the tumors, whereas tumor regrowth was observed for mice treated with 5 kBq [225Ac]Ac-PSMA-617 and only one out of six mice survived until the end of the study. The enhanced therapeutic efficacy of [225Ac]Ac-SibuDAB as compared to that of [225Ac]Ac-PSMA-617 and reasonable safety data qualify this novel radioligand as a candidate for targeted α-therapy of prostate cancer." @default.
- W4309462985 created "2022-11-28" @default.
- W4309462985 creator A5009635757 @default.
- W4309462985 creator A5027075021 @default.
- W4309462985 creator A5041743198 @default.
- W4309462985 creator A5047815496 @default.
- W4309462985 creator A5056614563 @default.
- W4309462985 creator A5079454182 @default.
- W4309462985 date "2022-11-17" @default.
- W4309462985 modified "2023-10-11" @default.
- W4309462985 title "[225Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [225Ac]Ac-PSMA-617" @default.
- W4309462985 cites W1140456871 @default.
- W4309462985 cites W1952786736 @default.
- W4309462985 cites W2030940240 @default.
- W4309462985 cites W2094108414 @default.
- W4309462985 cites W2218133630 @default.
- W4309462985 cites W2416252717 @default.
- W4309462985 cites W2473278896 @default.
- W4309462985 cites W2616958154 @default.
- W4309462985 cites W2784080506 @default.
- W4309462985 cites W2786988345 @default.
- W4309462985 cites W2789940608 @default.
- W4309462985 cites W2790757161 @default.
- W4309462985 cites W2799487694 @default.
- W4309462985 cites W2808022995 @default.
- W4309462985 cites W2887123205 @default.
- W4309462985 cites W2899588790 @default.
- W4309462985 cites W2945915427 @default.
- W4309462985 cites W2997044315 @default.
- W4309462985 cites W2999653667 @default.
- W4309462985 cites W3005807548 @default.
- W4309462985 cites W3029874672 @default.
- W4309462985 cites W3087151197 @default.
- W4309462985 cites W3108377814 @default.
- W4309462985 cites W3112030517 @default.
- W4309462985 cites W3113905045 @default.
- W4309462985 cites W3131801237 @default.
- W4309462985 cites W3176208875 @default.
- W4309462985 cites W3198881089 @default.
- W4309462985 cites W4210472822 @default.
- W4309462985 cites W4225538559 @default.
- W4309462985 cites W4225792535 @default.
- W4309462985 cites W4280539505 @default.
- W4309462985 cites W4280601090 @default.
- W4309462985 cites W4281623492 @default.
- W4309462985 cites W4281642705 @default.
- W4309462985 cites W4281752578 @default.
- W4309462985 cites W4298393564 @default.
- W4309462985 cites W4310462182 @default.
- W4309462985 doi "https://doi.org/10.3390/cancers14225651" @default.
- W4309462985 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36428743" @default.
- W4309462985 hasPublicationYear "2022" @default.
- W4309462985 type Work @default.
- W4309462985 citedByCount "8" @default.
- W4309462985 countsByYear W43094629852023 @default.
- W4309462985 crossrefType "journal-article" @default.
- W4309462985 hasAuthorship W4309462985A5009635757 @default.
- W4309462985 hasAuthorship W4309462985A5027075021 @default.
- W4309462985 hasAuthorship W4309462985A5041743198 @default.
- W4309462985 hasAuthorship W4309462985A5047815496 @default.
- W4309462985 hasAuthorship W4309462985A5056614563 @default.
- W4309462985 hasAuthorship W4309462985A5079454182 @default.
- W4309462985 hasBestOaLocation W43094629851 @default.
- W4309462985 hasConcept C121608353 @default.
- W4309462985 hasConcept C126322002 @default.
- W4309462985 hasConcept C150903083 @default.
- W4309462985 hasConcept C170493617 @default.
- W4309462985 hasConcept C185592680 @default.
- W4309462985 hasConcept C202751555 @default.
- W4309462985 hasConcept C207001950 @default.
- W4309462985 hasConcept C2776125364 @default.
- W4309462985 hasConcept C2780192828 @default.
- W4309462985 hasConcept C55493867 @default.
- W4309462985 hasConcept C67847695 @default.
- W4309462985 hasConcept C71924100 @default.
- W4309462985 hasConcept C86803240 @default.
- W4309462985 hasConcept C98274493 @default.
- W4309462985 hasConceptScore W4309462985C121608353 @default.
- W4309462985 hasConceptScore W4309462985C126322002 @default.
- W4309462985 hasConceptScore W4309462985C150903083 @default.
- W4309462985 hasConceptScore W4309462985C170493617 @default.
- W4309462985 hasConceptScore W4309462985C185592680 @default.
- W4309462985 hasConceptScore W4309462985C202751555 @default.
- W4309462985 hasConceptScore W4309462985C207001950 @default.
- W4309462985 hasConceptScore W4309462985C2776125364 @default.
- W4309462985 hasConceptScore W4309462985C2780192828 @default.
- W4309462985 hasConceptScore W4309462985C55493867 @default.
- W4309462985 hasConceptScore W4309462985C67847695 @default.
- W4309462985 hasConceptScore W4309462985C71924100 @default.
- W4309462985 hasConceptScore W4309462985C86803240 @default.
- W4309462985 hasConceptScore W4309462985C98274493 @default.
- W4309462985 hasFunder F4320320924 @default.
- W4309462985 hasIssue "22" @default.
- W4309462985 hasLocation W43094629851 @default.
- W4309462985 hasLocation W43094629852 @default.
- W4309462985 hasLocation W43094629853 @default.
- W4309462985 hasLocation W43094629854 @default.
- W4309462985 hasLocation W43094629855 @default.